Trials
2 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 2/3
- “This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.”In the company’s words, NCT07432854 on ClinicalTrials.gov
Other drugs for Moderate to Severe Plaque Psoriasis
- ZasocitinibTakeda · Phase 3
- TQH3906Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PiclidenosonCan-Fite BioPharma · Phase 3
- Total coumarin creamPsoriasis Research Institute of Guangzhou · Phase 3
- RisankizumabAbbVie · Phase 3
Coming up2
- 31 Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- 29 Feb 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 29 Feb 2028 | A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis | |
| Phase 2Not yet recruiting | 31 Jan 2027 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026